Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, Raya JM, Pérez-Encinas M, Ayala R, Ferrer-Marín F, Velez P, Mora E, Fox ML, Hernández-Rivas JM, Xicoy B, Mata-Vázquez MI, García-Fortes M, Pérez-López R, Angona A, Cuevas B, Senín A, Ramírez MJ, Ramírez-Payer A, Gómez-Casares MT, Martínez-Valverde C, Magro E, Steegmann JL, Durán MA, García-Hernández C, Gasior M, de Villambrosia SG, Alvarez-Larrán A, Pereira A; Spanish MPN Group (GEMFIN). Hernández-Boluda JC, et al. Among authors: ayala r. Br J Haematol. 2022 Nov;199(4):529-538. doi: 10.1111/bjh.18440. Epub 2022 Sep 12. Br J Haematol. 2022. PMID: 36089912
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: ayala r. Ann Hematol. 2015 Jun;94(6):911-8. doi: 10.1007/s00277-015-2330-2. Epub 2015 Feb 14. Ann Hematol. 2015. PMID: 25680896
Chronic myeloid leukaemia in Spain: Its presentation characteristics have changed. Spanish section of the EUTOS population-based registry.
Osorio S, Casado LF, Giraldo P, Maestro B, Andrade M, Redondo S, García-Gutiérrez V, Ayala R, Garcia N, Steegmann JL. Osorio S, et al. Among authors: ayala r. Rev Clin Esp (Barc). 2016 Aug-Sep;216(6):293-300. doi: 10.1016/j.rce.2016.03.001. Epub 2016 Apr 6. Rev Clin Esp (Barc). 2016. PMID: 27061504 English, Spanish.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Alvarez-Larrán A, et al. Among authors: ayala r. Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12. Haematologica. 2016. PMID: 27175028 Free PMC article.
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology.
Martínez-Laperche C, Kwon M, Franco-Villegas AC, Chillón MC, Castro N, Anguita E, Dolz S, Rodríguez-Medina C, Hermosín L, Bellón JM, Prieto-Conde MI, Barragán E, Gómez-Casares M, Ayala R, Martínez-López J, González-Díaz M, Díez-Martin JL, Buño I; Cooperative Group for Molecular Biology in Haematology (GBMH). Martínez-Laperche C, et al. Among authors: ayala r. Br J Haematol. 2018 May;181(4):542-546. doi: 10.1111/bjh.14635. Epub 2017 Apr 3. Br J Haematol. 2018. PMID: 28369773 Free article. No abstract available.
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Pastor-Galán I, et al. Among authors: ayala r. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007. Epub 2020 Jan 21. Med Clin (Barc). 2020. PMID: 31980217 English, Spanish.
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
Onecha E, Ruiz-Heredia Y, Martínez-Cuadrón D, Barragán E, Martinez-Sanchez P, Linares M, Rapado I, Perez-Oteyza J, Magro E, Herrera P, Rojas JL, Gorrochategui J, Villoria J, Boluda B, Sargas C, Ballesteros J, Montesinos P, Martínez-López J, Ayala R. Onecha E, et al. Among authors: ayala r. Br J Haematol. 2020 May;189(4):672-683. doi: 10.1111/bjh.16432. Epub 2020 Feb 18. Br J Haematol. 2020. PMID: 32068246 Free article.
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernandez-Rodriguez C, Luño E, García Hernandez C, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boqué C, García-Gutierrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de Los Reyes-García AM, Besses C, Vicente V, Alvarez-Larrán A, Teruel-Montoya R, González-Conejero R, Martínez C; GEMFIN Group. Ferrer-Marín F, et al. Among authors: ayala r. Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27. Leukemia. 2020. PMID: 32107471
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM; Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH). Ribera J, et al. Among authors: ayala r. Br J Haematol. 2022 Feb;196(3):670-675. doi: 10.1111/bjh.17844. Epub 2021 Sep 21. Br J Haematol. 2022. PMID: 34549416 Free article.
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas). Alvarez-Larrán A, et al. Among authors: ayala r. Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13. Cancer. 2022. PMID: 35417564 Free PMC article.
370 results